Design, Synthesis, and Anticancer Activity of New Oxadiazolyl‐Linked and Thiazolyl‐Linked Benzimidazole Arylidines, Thioglycoside, and Acyclic Analogs

Nassar, Ibrahim F.; kady, Dina S. El; Awad, Hanem M.; El‐Sayed, Wael A.

doi:10.1002/jhet.3496

Cited by 15 publications

(8 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nassar et al [61] synthesized derivatives from 2‐[(4‐thiazolylmethyl)thio]‐1 H ‐benzimidazole. These synthesized compounds were evaluated for their anti‐cancer activity against MCF‐7 human cancer cell lines with doxorubicin as the standard drug.…”

Section: Benzimidazole As Target Oriented Anticancer Agentsmentioning

confidence: 99%

Benzimidazole based derivatives as anticancer agents: Structure activity relationship analysis for various targets

Satija

Sharma

Madan

et al. 2021

Journal of Heterocyclic Chem

View full text Add to dashboard Cite

Benzimidazole, the benzo derivative of imidazole, is a class of bicyclic aromatic organic compound consisting of six‐membered benzene ring fused to five‐membered imidazole at 4‐ and 5‐positions of the imidazole ring. It is a vital pharmacophore of many biologically active heterocyclic compounds with a variety of pharmacological activities. Over the time, benzimidazole and its derivatives have evolved as vibrant heterocyclic systems due to their potency in a wide range of bioactive compounds like analgesics, antifungals, anti‐inflammatory, antihypertensives, proton pump inhibitors, anti‐HIV, antiviral, and so on. Multi‐drug resistance in cancer that led to the failure of many chemotherapeutic drugs is a major concern. Various approaches are being developed to overcome this problem. One of them is target based drug discovery, which is an effective method to develop a novel anticancer drug. To develop newer drugs, previously reported work needs to be studied. Keeping this in mind, last 5 years literature on benzimidazole used as anticancer agents has been reviewed and summarized in the paper herein. This review article along with the target of cancer also deal with structure activity relationship of various compounds having benzimidazole ring.

show abstract

Section: Benzimidazole As Target Oriented Anticancer Agentsmentioning

confidence: 99%

Benzimidazole based derivatives as anticancer agents: Structure activity relationship analysis for various targets

Satija

Sharma

Madan

et al. 2021

Journal of Heterocyclic Chem

View full text Add to dashboard Cite

show abstract

“…Molecular hybridization is an effective and simple tool to covalently merge two drug pharmacophores to obtain a single molecule [ 35 ]. Considering the facts discussed above regarding the biological significance of indole, thiadiazole, triazole and glycoside fragments ( Figure 2 ) and upon the continuation of our research in the discovery of potent anticancer targets [ 36 , 37 , 38 , 39 , 40 , 41 ], it was conceived that the joining of these pharmacophores into one nucleus through a fragment-based drug design approach would develop highly potent anticancer targets. Herein, a novel series of glycosides incorporated into indole–thiadiazole–triazole bases or substituted arylacetamino–triazole hybrids were designed, synthesized and evaluated for their cytotoxic activities.…”

Section: Introductionmentioning

confidence: 99%

Design, Synthesis, Anticancer Activity and Molecular Docking of New 1,2,3-Triazole-Based Glycosides Bearing 1,3,4-Thiadiazolyl, Indolyl and Arylacetamide Scaffolds

et al. 2022

View full text Add to dashboard Cite

New 1,3,4-thiadiazole thioglycosides linked to a substituted arylidine system were synthesized via heterocyclization via click 1,3-dipolar cycloaddition. The click strategy was used for the synthesis of new 1,3,4-thiadiazole and 1,2,3-triazole hybrid glycoside-based indolyl systems as novel hybrid molecules by reacting azide derivatives with the corresponding acetylated glycosyl terminal acetylenes. The cytotoxic activities of the compounds were studied against HCT-116 (human colorectal carcinoma) and MCF-7 (human breast adenocarcinoma) cell lines using the MTT assay. The results showed that the key thiadiazolethione compounds, the triazole glycosides linked to p-methoxyarylidine derivatives and the free hydroxyl glycoside had potent activity comparable to the reference drug, doxorubicin, against MCF-7 human cancer cells. Docking simulation studies were performed to check the binding patterns of the synthesized compounds. Enzyme inhibition assay studies were also conducted for the epidermal growth factor receptor (EGFR), and the results explained the activity of a number of derivatives.

show abstract

“…On the other hand, glycoside and their analogs have been revealed as an important bioactive group of compounds with anticancer, antiviral, and antimicrobial activity. The therapeutic importance of this scaffold motivated us to develop selective procedures for the synthesis of new derivatives of pyridine incorporating pyrazolyl, imidazolyl, thienyl, and glycosyl moieties in which substituents could be arranged in a pharmacophoric pattern to display high order of anticancer activity [ 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ].…”

Section: Introductionmentioning

confidence: 99%

Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity

et al. 2021

Self Cite

View full text Add to dashboard Cite

New pyridine, pyrazoloyridine, and furopyridine derivatives substituted with naphthyl and thienyl moieties were designed and synthesized starting from 6-(naphthalen-2-yl)-2-oxo-4-(thiophen-2-yl)-1,2-dihydropyridine-3-carbonitrile (1). The chloro, methoxy, cholroacetoxy, imidazolyl, azide, and arylamino derivatives were prepared to obtain the pyridine-−C2 functionalized derivatives. The derived pyrazolpyridine-N-glycosides were synthesized via heterocyclization of the C2-thioxopyridine derivative followed by glycosylation using glucose and galactose. The furopyridine derivative 14 and the tricyclic pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine 15 were prepared via heterocyclization of the ester derivative followed by a reaction with formamide. The newly synthesized compounds were evaluated for their ability to in vitro inhibit the CDK2 enzyme. In addition, the cytotoxicity of the compounds was tested against four different human cancer cell lines (HCT-116, MCF-7, HepG2, and A549). The CDK2/cyclin A2 enzyme inhibitory results revealed that pyridone 1, 2-chloro-6-(naphthalen-2-yl)-4-(thiophen-2-yl)nicotinonitrile (4), 6-(naphthalen-2-yl)-4-(thiophen-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-amine (8), S-(3-cyano-6-(naphthaen-2-yl)-4-(thiophen-2-yl)pyridin-2-yl) 2-chloroethanethioate (11), and ethyl 3-amino-6-(naphthalen-2-yl)-4-(thiophen-2-yl)furo[2,3-b]pyridine-2-carboxylate (14) are among the most active inhibitors with IC50 values of 0.57, 0.24, 0.65, 0.50, and 0.93 µM, respectively, compared to roscovitine (IC50 0.394 μM). Most compounds showed significant inhibition on different human cancer cell lines (HCT-116, MCF-7, HepG2, and A549) with IC50 ranges of 31.3–49.0, 19.3–55.5, 22.7–44.8, and 36.8–70.7 μM, respectively compared to doxorubicin (IC50 40.0, 64.8, 24.7 and 58.1 µM, respectively). Furthermore, a molecular docking study suggests that most of the target compounds have a similar binding mode as a reference compound in the active site of the CDK2 enzyme. The structural requirements controlling the CDK2 inhibitory activity were determined through the generation of a statistically significant 2D-QSAR model.

show abstract

Design, Synthesis, and Anticancer Activity of New Oxadiazolyl‐Linked and Thiazolyl‐Linked Benzimidazole Arylidines, Thioglycoside, and Acyclic Analogs

Cited by 15 publications

References 53 publications

Benzimidazole based derivatives as anticancer agents: Structure activity relationship analysis for various targets

Benzimidazole based derivatives as anticancer agents: Structure activity relationship analysis for various targets

Design, Synthesis, Anticancer Activity and Molecular Docking of New 1,2,3-Triazole-Based Glycosides Bearing 1,3,4-Thiadiazolyl, Indolyl and Arylacetamide Scaffolds

Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity

Contact Info

Product

Resources

About